Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 3/20 | 1.00 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.38 |
| ▸ | HSD11B2 | P80365 | 3/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | PDE5A | O76074 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14433407 | 0.98 | BACE1 (0.97) | BACE1LTA4HALDH1A1L3MBTL1NPC1 | |
| SCHEMBL8280838 | 0.97 | BACE1 (0.94) | BACE1LTA4HALDH1A1L3MBTL1NPC1 | |
| SCHEMBL8281540 | 0.88 | BACE1 (0.78) | BACE1ALDH1A1L3MBTL1NPC1RAB9A | |
| SCHEMBL8282517 | 0.85 | BACE1 (0.74) | BACE1ALDH1A1L3MBTL1NPC1RAB9A | |
| SCHEMBL8280834 | 0.85 | BACE1 (0.74) | BACE1LTA4HALDH1A1L3MBTL1NPC1 | |
| SCHEMBL8280899 | 0.85 | BACE1 (0.74) | BACE1ALDH1A1L3MBTL1NPC1RAB9A | |
| SCHEMBL27183888 | 0.85 | BACE1 (0.74) | BACE1LTA4HALDH1A1L3MBTL1NPC1 | |
| SCHEMBL3139632 | 0.84 | BACE1 (0.73) | BACE1ALDH1A1L3MBTL1NPC1RAB9A | |
| SCHEMBL8280887 | 0.84 | BACE1 (0.72) | BACE1ALDH1A1L3MBTL1RAB9ASLC6A4 | |
| SCHEMBL8281533 | 0.83 | BACE1 (0.71) | BACE1ALDH1A1L3MBTL1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218629-A1 | THERAPEUTIC COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF DIASTOLIC DYSFUNCTION | Ambetex Pty Ltd (AU) | 2023-07-13 | — | — | US | disclosed |
| US-20230218629-A1 | THERAPEUTIC COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF DIASTOLIC DYSFUNCTION | Ambetex Pty Ltd (AU) | 2023-07-13 | — | — | US | disclosed |
| US-20070203147-A1 | 2-Aminothiazole Compounds Useful As Aspartyl Protease Inhibitors | MERCK SHARP & DOHME CORP. | 2007-08-30 | — | — | US | disclosed |
| US-20070203147-A1 | 2-Aminothiazole Compounds Useful As Aspartyl Protease Inhibitors | MERCK SHARP & DOHME CORP. | 2007-08-30 | — | — | US | disclosed |
| WO-2005097767-A1 | 2-AMINOTHIAZOLE COMPOUNDS USEFUL AS ASPARTYL PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203147-A1 | 2-Aminothiazole Compounds Useful As Aspartyl Protease Inhibitors | BACE2, BACE1, APP | BACE1 2/4885LTA4H 639/4885ALDH1A1 1717/4885 |
| US-20230218629-A1 | THERAPEUTIC COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF DIASTOLIC DYSFUNCTION | TNNI3, TNNT2, TNNC1 | BACE1 5/4885LTA4H 3297/4885ALDH1A1 3848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.